Stock Analysis

China Shineway Pharmaceutical Group Full Year 2022 Earnings: Beats Expectations

Published
SEHK:2877
Source: Shutterstock

China Shineway Pharmaceutical Group (HKG:2877) Full Year 2022 Results

Key Financial Results

  • Revenue: CN¥3.95b (up 23% from FY 2021).
  • Net income: CN¥722.8m (up 30% from FY 2021).
  • Profit margin: 18% (up from 17% in FY 2021). The increase in margin was driven by higher revenue.
  • EPS: CN¥0.96 (up from CN¥0.74 in FY 2021).

2877 Products In Clinical Trials

  • Phase III: 3.
earnings-and-revenue-growth
SEHK:2877 Earnings and Revenue Growth March 31st 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

China Shineway Pharmaceutical Group Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 8.8%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are up 2.4% from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with China Shineway Pharmaceutical Group.

Valuation is complex, but we're helping make it simple.

Find out whether China Shineway Pharmaceutical Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.